Document is current
Any future updates will be listed below
-
Authors
Solberg, Steinar https://orcid.org/0000-0002-8206-5435
Slørdahl, Kathinka Schmidt
Aanerud, Marianne
Brustugun, Odd Terje
Grønberg, Bjørn Henning
Helbekkmo, Nina
Helland, Åslaug
Nilssen, Yngvar
- License Information
-
More Information
Article History
Received: 20 May 2025
Revised: 18 August 2025
Accepted: 8 September 2025
First Online: 9 October 2025
Competing interests
: Professor Grønberg has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from MSD, Janssen, AstraZeneca, Pfizer, Eli Lilly, Gilead, and BMS. He has participated on a Data Safety Monitoring Board or Advisory Board for MSD, Janssen, Accord, AstraZeneca, and BMS.MAA has received lecture honoraria from BMS and AstraZeneca. Professor Helland has received research grants from Roche, AstraZeneca, Novartis, Incyte, Eli Lilly, BMS, Ultimovacs, Merck, GSK, Illumina, Nanopore, and Johnson & Johnson. All funding has been transferred to the hospital. She has received consulting fee from ABBVIE, Takeda, AstraZeneca, Roche, Pfizer, Janssen, EliLilly, BMS, PierreFabre, Bayer, MSD, Novartis, Merck, Sanofi, and Medicover. All fees have been transferred to the hospital. All other authors declare no competing interests.
: As the Cancer Registry of Norway is statutory, there is no need for consent for collecting data and presenting results on a group basis. This study is performed in accordance with the regulations for the Cancer Registry of Norway, and no approval from an ethics committee or informed consent from patients is needed.
